Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07015190 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Darovasertib in Primary Uveal Melanoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 87 → 94 locationsv6
  2. Study sites: 75 to 87 Start date changed from estimate of Oct 2025 to Jan 25, 2026v5 Show 1 more changeShow less
    • Start date changed from estimate of Oct 2025 to Jan 25, 2026
  3. Study sites: 60 to 75v4
  4. Trial status: Not Yet Recruiting to Recruiting Primary completion date: May 7, 2027 to Oct 2030 · Study sites: 0 to 60 · Completion date: Dec 7, 2027 to Mar 2031 · 1 morev3 Show 4 more changesShow less
    • Primary completion date: May 7, 2027 to Oct 2030
    • Study sites: 0 to 60
    • Completion date: Dec 7, 2027 to Mar 2031
    • Start date: Sep 30, 2025 to Oct 2025
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IDEAYA Biosciences
11 trials monitored
See all monitored trials
Melanoma
1,026 trials monitored
See 48 trials at risk
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Trial Details
NCT Number NCT07015190
Lead Sponsor IDEAYA Biosciences
Conditions Uveal Melanoma
Enrollment 520 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov